Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Mutations in ATP13A2 lead to Kufor-Rakeb syndrome, a parkinsonism with dementia. ATP13A2 belongs to the P-type transport ATPases, a large family of primary active transporters that exert vital cellular functions. However, the cellular function and transported substrate of ATP13A2 remain unknown. To discuss the role of ATP13A2 in neurodegeneration, we first provide a short description of the architecture and transport mechanism of P-type transport ATPases. Then, we briefly highlight key P-type ATPases involved in neuronal disorders such as the copper transporters ATP7A (Menkes disease), ATP7B (Wilson disease), the Na(+)/K(+)-ATPases ATP1A2 (familial hemiplegic migraine) and ATP1A3 (rapid-onset dystonia parkinsonism). Finally, we review the recent literature of ATP13A2 and discuss ATP13A2's putative cellular function in the light of what is known concerning the functions of other, better-studied P-type ATPases. We critically review the available data concerning the role of ATP13A2 in heavy metal transport and propose a possible alternative hypothesis that ATP13A2 might be a flippase. As a flippase, ATP13A2 may transport an organic molecule, such as a lipid or a peptide, from one membrane leaflet to the other. A flippase might control local lipid dynamics during vesicle formation and membrane fusion events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Phylogeny.fr: robust phylogenetic analysis for the non-specialist
Dereeper, A., Guignon, V., Blanc, G., Audic, S., Buffet, S., Chevenet, F., Dufayard, J.-F., Guindon, S., Lefort, V., Lescot, M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn180 · Cited by 4,700 · cited 1×
“The phylogenetic tree was rendered using www. phylogeny.fr (Dereeper et al., 2008, 2010). and charge gradients (Kuhlbrandt, 2004; Palmgren and Nissen, 2011).”
MethodImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 2×
“…can have a significant impact on the basal fusogenic properties of synaptic vesicles. α -synuclein aggregates accumulate in PD and are cleared via various routes, mainly including the ubiquitin-proteasome sys-tem, autophagy and lysosomal degradation pathways (Webb et al., 2003; Cuervo et al., 2004).”
BackgroundLees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429 · cited 4×
“…control the delivery of α - synuclein to the lysosomes by regulating different autophagy pathways such as macro-autophagy (Dehay et al., 2012b; Usenovic et al., 2012a) and chaperone-mediated autophagy, two autophagic routes that control α -synuclein turnover (Webb et al., 2003; Mak et al., 2010).”
BackgroundInfluentialRamirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825
Zinc in the physiology and pathology of the CNS
Sensi, S. L., Paoletti, P., Bush, A. I., & Sekler, I. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2734 · Cited by 759 · cited 4×
“Zn 2+ dyshomeostasis has been associated with a variety of neurological 19 disorders (158).”
BackgroundInfluentialLysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2
Ferguson, C. J., Lenk, G. M., & Meisler, M. H. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp460 · Cited by 202 · cited 1×
“Alternatively, changes in the lysosomal lipid distribution may regulate autophagy pathways, which are known to be sensitive to changes in the lipid environment (Ferguson et al., 2009; Rodriguez-Navarro et al., 2012).”
Cited by
Manganese Is Essential for Neuronal Health
Horning, K. J., Caito, S. W., Tipps, K. G., Bowman, A. B., & Aschner, M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034419 · Cited by 602
Colacurcio, D. J., & Nixon, R. A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.05.004 · Cited by 548
“Interestingly, ATP13A2 mutations also cause a lysosomal storage disease, neuronal ceroid lipofuscinosis (NCL) (Bras et al., 2012), and NCL shares overlapping pathological features with both PD and KRS (Deng et al., 2015; van Veen et al., 2014).”
BackgroundMechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases
Nixon, R. A., & Rubinsztein, D. C. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00757-5 · Cited by 435
“ATP13A2 is considered a pH modulator given that its mutation and/or loss leads to accumulation of these polyamines 152–154 , pH elevation, autophagosome and lysosome build-up 155–157 and earlier cell death by apoptosis than treated wild-type cells 151 .”
Peres, T. V., Schettinger, M. R. C., Chen, P., Carvalho, F., Avila, D. S., Bowman, A. B., & Aschner, M. (2016) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-016-0099-0 · Cited by 386
Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders
Upadhyay, R. K. (2015) · Journal of Lipids · doi:10.1155/2015/971453 · Cited by 360
ATP13A2 deficiency disrupts lysosomal polyamine export
van Veen, S., Martin, S., Van den Haute, C., Benoy, V., Lyons, J., Vanhoutte, R., Kahler, J. P., Decuypere, J.-P., Gelders, G., Lambie, E., et al. (2020) · Nature · doi:10.1038/s41586-020-1968-7 · Cited by 332
Self-citationThe role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms
Park, J., Blair, N. F., & Sue, C. M. (2015) · Movement Disorders · doi:10.1002/mds.26243 · Cited by 173
“Sequence homology indicates that ATP13A2 is a member of the P-type ATPase family, most of which are cation transporters.(36) Interestingly, the Wilson’s disease protein (also known as ATP7B) is a member of this family and functions as a Cu transporter.”
BackgroundEstrada-Cuzcano, A., Martin, S., Chamova, T., Synofzik, M., Timmann, D., Holemans, T., Andreeva, A., Reichbauer, J., De Rycke, R., Chang, D.-I., et al. (2017) · Brain · doi:10.1093/brain/aww307 · Cited by 166
Self-citationATP13A3 is a major component of the enigmatic mammalian polyamine transport system
Hamouda, N. N., Van den Haute, C., Vanhoutte, R., Sannerud, R., Azfar, M., Mayer, R., Cortés Calabuig, Á., Swinnen, J. V., Agostinis, P., Baekelandt, V., et al. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013908 · Cited by 85
Self-citationBortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
What lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
Metadata
- Authors
- van Veen, S., Sørensen, D. M., Holemans, T., Holen, H. W., Palmgren, M. G., & Vangheluwe, P.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-05-27
- Volume
- 7
- Pages
- 48-48
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2036697195
- Cited by
- 88
- References
- 11
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.